a-HTT50CAGWT_Overlay__TUBB3(G)_MAP2(R)_DAPI(B)_ (1)

cat no | ioEA1004

ioGlutamatergic Neurons

HTT 50CAG/WT

Human iPSC-derived Huntington’s disease model

A rapidly maturing, consistent and scalable isogenic system to study Huntington’s disease.

ioGlutamatergic Neurons HTT50CAG/WT are opti-ox™ precision reprogrammed glutamatergic neurons containing a genetically engineered heterozygous 50 CAG trinucleotide repeat expansion in exon 1 of the HTT gene. Human stem cells, within days, convert consistently into mature, functional glutamatergic neurons that express pan-neuronal and glutamatergic markers TUBB3, MAP2 and VGLUT2 by day 11, as well as the disease-relevant Huntingtin protein.

bit.bio’s wild type ioGlutamatergic Neurons™ form the genetically matched control for the ioGlutamatergic Neurons HTT50CAG/WT disease model. This physiologically-relevant isogenic pairing offers a fast and easy-to-use next-generation model to investigate into the impact of gene function on disease progression.

Request a quote

Once your quote request has been submitted, one of our sales team will be in contact.

Unsure where to start?

Get in touch and we'll guide the way!

Benchtop benefits

easy_0

Easy-to-use

Cells are programmed to mature rapidly upon revival with a simple two-phase protocol using an open-sourced medium.

scalable_0

Scalable

Industrial scale quantities are available with industry-leading seeding densities, and at a price point that allows the cells to be used from research to high throughput screening.

defined_0

Make True Comparisons

Be confident in your data. ioDisease Model Cells can be paired with ioWild Type Cells to provide a genetically matched, highly characterised background for the precise analysis of gene function.

Product information

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 48, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast)

Vial size

Small: >1 x 10 viable cells
Large: >5 x 10 viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation

Product use

These cells are for research use only

Differentiation method

opti-ox cellular reprogramming

Recommended seeding density

30,000 cells/cm2

User storage

LN2 or -150°C

Format

Cryopreserved cells

Applications

Basic research
Drug discovery
Disease modelling
Electrophysiological assays (MEA)
Co-culture studies

Genetic modification

Heterozygous - HTT 50 CAG repeat expansion

Technical data

Ready within days

ioGlutamatergic Neurons HTT50CAG/WT generated by transcription factor-driven reprogramming of iPSCs using opti-ox technology

Video capturing the rapid morphological changes of the ioGlutamatergic Neurons HTT 50CAG/WT upon revival of the cryopreserved product over an 11-day culturing period. The observed rapid morphological changes are enabled by opti-ox precision reprogramming.

Highly characterised and defined

ioGlutamatergic Neurons HTT50CAG/WT express neuron-specific markers with protein expression highly reminiscent to the isogenic control

ioGlut-HTT50CAG_WT-ICC

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons HTT50CAG/WT compared to the isogenic control. 100X magnification.

ioGlutamatergic Neurons HTT50CAG/WT form structural networks by day 11

ioGlut-HTT50CAG_WT-brightfield

ioGlutamatergic Neurons HTT50CAG/WT mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thawing; 100X magnification.

ioGlutamatergic Neurons HTT50CAG/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following reprogramming

ioGlutamatergic Neurons HTT50CAG_WT demonstrate gene expression-min

Gene expression analysis demonstrates that ioGlutamatergic Neurons HTT50CAG/WT (50CAG/WT) and the isogenic control (WT) at day 11 lack the expression of pluripotency makers (NANOG and OCT4) whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels assessed by RT-qPCR (data expressed relative to the parental hiPSC control (iPSC Control), normalised to HMBS). Data represents day 11 post-revival samples; n=2 biological replicates.

Disease-related Huntingtin (HTT) is expressed in ioGlutamatergic Neurons HTT50CAG/WT

Disease-related Huntingtin (HTT) is expressed in ioGlutamatergic Neurons HTT50CAG_WT -min

RT-qPCR analysis demonstrates similar expression level of the Huntingtin gene in both wild type ioGlutamatergic Neurons (WT) and ioGlutamatergic Neurons HTT50CAG/WT (50CAG/WT) at day 11 post-revival (n=2 replicates). cDNA samples of the parental iPSC line
(iPSC control) were included as a reference.

Genotype validation

Genotype validation of heterozygous 50 CAG repeat expansion

Genotype validation of heterozygous 50 CAG repeat expansion

(A) Successful on-target integration into one HTT allele confirmed by gel electrophoresis. Genotyping primers flanking the endogenous HTT CAG repeat expansion region produce a band at approximately 320 bps, by PCR, in both isogenic control (ioGlutamatergic Neurons) and disease model (ioGlutamatergic Neurons HTT50CAG/WT). PCR fragments at 395 bps detect on-target gene editing and introduction of a 50 CAG repeat expansion in ioGlutamatergic Neurons HTT50CAG/WT only. (B) Amplicon PCR of the plasmid donor reveals no random integration in genomic DNA from targeted colonies via gel electrophoresis. Off-target random insertion of the donor template (used to introduce the 50 CAG repeat expansion at the WT HTT locus) is detected by PCR amplification of the donor vector backbone. This is not detected in the samples from ioGlutamatergic Neurons HTT50CAG/WT.

Genotype validation of the number of CAG repeats

enotype validation of the number of CAG repeats

NGS-amplicon sequencing confirms the number of CAG repeats in wild type ioGlutamatergic Neurons (yellow) and ioGlutamatergic Neurons HTT50CAG/WT (orange). The number of CAG repeats shows a peak at the normal physiological range of 24 for both the wild type and mutant cells. The 50 CAG repeat was detected only in the mutant cells (orange) confirming the successful introduction of a heterozygous 50 CAG repeat expansion in ioGlutamatergic Neurons HTT50CAG/WT.

Industry leading seeding density

Do more with every vial
ioGlut-HTT50CAG_WT-well_plate-2

The recommended seeding density of our human iPSC-derived Huntington’s disease model and isogenic control has been optimised and validated making it possible to have a cost point of under £0.67 per well (~$0.79) (96 well plate, seeding density 30,000 cells/cm2, Large vial size).

This means scientists are able to do more with every vial and expand experimental design within budget without losing out on quality. Resulting in more experimental conditions, more repeats, and more confidence in the data.

One Small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plate.

One Large vial can plate a minimum of 3.6 x 24-well plate, 5.4 x 96-well plate, or 7.75 x 384-well plates.

Cells arrive ready to plate

HTT-Timeline-min

ioGlutamatergic Neurons HTT50CAG/WT are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: Induction, which is carried out at bit.bio (Phase 0), Stabilisation for 4 days (Phase 1), and Maintenance (Phase 2) during which the ioGlutamatergic Neurons HTT50CAG/WT mature. Phases 1 and 2 after revival of cells are carried out at the customer site.

Product resources

How to culture ioGlutamatergic Neurons HTT 50CAG/WT™ Video tutorial
How to culture ioGlutamatergic Neurons HTT 50CAG/WT™

Madeleine Garrett | Field Application Scientist
bit.bio

Watch now
Introducing ioGlutamatergic Neurons HTT 50CAG/WT™ | A next-generation approach to study Huntington's disease Video
Introducing ioGlutamatergic Neurons HTT 50CAG/WT™ | A next-generation approach to study Huntington's disease

bit.bio

Watch now
Improving Huntington’s disease drug discovery with new reproducible disease models Webinar
Improving Huntington’s disease drug discovery with new reproducible disease models

Dr Emma V Jones | Senior Scientist | Medicines Discovery Catapult

Dr Tony Oosterveen | Senior Scientist and CNS Lead | bit.bio

Watch now
ioGlutamatergic Neurons HTT 50CAG/WT™ Brochure
ioGlutamatergic Neurons HTT 50CAG/WT™

bit.bio

Download
Modelling human neurodegenerative diseases in research & drug discovery Webinar
Modelling human neurodegenerative diseases in research & drug discovery

Dr Mariangela Iovino | Group Leader | Charles River
Dr Tony Oosterveen | Senior Scientist | bit.bio

Watch now
Modelling neurodegeneration using a human isogenic system Poster
Modelling neurodegeneration using a human isogenic system

Oosterveen | et al 
bit.bio

Download

Addressing current challenges of in vitro cell models 

Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.

bit-bio_Addressing the challenges of cell models_Blog_Image1200x755

Related products

ioGlutamatergic Neurons MAPT N279K/WT™ ioDisease Model
ioGlutamatergic Neurons MAPT N279K/WT™ cat no. io1009
Order now
ioGlutamatergic Neurons MAPT P301S/WT™ ioDisease Model
ioGlutamatergic Neurons MAPT P301S/WT™ cat no. io1015
Order now
ioGlutamatergic Neurons MAPT P301S/P301S™ ioDisease Model
ioGlutamatergic Neurons MAPT P301S/P301S™ cat no. io1018
Order now
ioMicroglia™ ioWild Type
ioMicroglia™ cat no. ioA021
Order now
ioGlutamatergic Neurons TDP-43 M337V™ ioDisease Model
ioGlutamatergic Neurons TDP-43 M337V™ cat no. ioEA1005 | ioEA1006
Order now
ioGABAergic Neurons™ ioWild Type
ioGABAergic Neurons™ cat no. ioEA1003S
Order now
ioSkeletal Myocytes™ ioWild Type
ioSkeletal Myocytes™ cat no. io1002
Order now
ioGlutamatergic Neurons™ ioWild Type
ioGlutamatergic Neurons™ cat no. io1001
Order now

Wild Type and Isogenic Disease Model cells: A true comparison.

Further your disease research by pairing our wild type cells with isogenic disease models.

bitbio-vials-Wild_and_Disease-staggered-2500px_wide

Related pages

Discover ioCells Learn about our range of human iPSC-derived cells for research and drug discovery
Resources Explore our latest scientific insights, webinars, blogs and videos
Our platform Discover the cell identity coding platform that powers our ioCells